Swiss trial resumes with NewLink/Merck Ebola vaccine
This article was originally published in Scrip
Executive Summary
Swiss researchers on 5 January resumed a trial testing an experimental Ebola vaccine from NewLink Genetics and its partner Merck, which had been temporarily paused last month after reports of joint pain in healthy volunteers.